CON enters its Q1 2026 earnings print today riding an unusual wave of options optimism — and a sharp divergence from its healthcare peers.
Options positioning is as bullish as it has been all year. The put/call ratio has collapsed to 0.02, less than a third of its 20-day average of 0.03, and close to the 52-week floor of 0.007. That reflects an almost complete absence of downside hedging relative to call activity — a setup that looks more like aggressive bullish speculation than cautious hedging into a binary event. The stock's price action adds context: CON gained 12.4% over the past month and another 5% on the week, closing at $23.60 on Thursday.
That outperformance is striking against the peer backdrop. Healthcare names broadly struggled on the week — ENSG fell 6.6%, MCK dropped 7.4%, and HSIC slid 5.5%. CON moved in the opposite direction throughout. Whether that reflects genuine fundamental divergence or pre-earnings positioning compression, today's print is the first real test of whether the move was warranted.
The fundamental picture supports a moderate bull case. Analysts who last updated coverage in early March carried a consensus mean target of $29.00 — roughly 23% above Thursday's close — with Wells Fargo and RBC Capital both maintaining constructive ratings. Note that those updates are around 65 days old, predating much of the recent rally; the gap between current price and target has narrowed significantly. On an EV/EBITDA basis, the stock trades near 10.5x, with the multiple rising roughly 0.8x over the past 30 days as price has moved ahead of estimates. EPS momentum ranks in the 57th percentile and the dividend score is in the 95th percentile, suggesting income-focused holders have a strong anchor.
Short sellers offer little pushback. Short interest has fallen about 18% over the past month to just 1.6% of the free float. Borrowing costs remain negligible at under 0.45%, and availability in the lending market is wide — well below the 52-week high in utilization terms. There is no borrow squeeze dynamic at work here. What today's report will actually test is whether the operational results — revenue growth, margin trajectory, and full-year guidance — can justify both the recent re-rating and the almost entirely one-sided call positioning that preceded it.
See the live data behind this article on ORTEX.
Open CON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
